Daniel J. Becker, MD

home / authors / daniel-j-becker-md

Articles

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

Benjamin P. Levy, MD;Parth Rao, MD;Daniel J. Becker, MD;Kevin Becker, MD

July 16th 2016

In this article, we review the available literature addressing the competing treatment strategies in EGFR-Positive Lung Cancer and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.

The Time for Low-Dose Computed Tomography Screening Is Now: A Medical Oncologist Perspective

Benjamin P. Levy, MD;Daniel J. Becker, MD

November 15th 2014

The NLST is a landmark trial demonstrating that implementation of low-dose CT screening lowers lung cancer–related mortality. We must put the study results and cost-effectiveness analyses in the context of the staggering statistics: up to 65% of lung cancer patients present with advanced-stage disease where treatments are often costly, toxic, and only palliative in nature.

Double Trouble: A Case of Concurrent De Novo T790M and L858R EGFR Mutations in Treatment-Naive Advanced Non–Small-Cell Lung Cancer

Ashish Saxena, MD, PhD;Misako Nagasaka, MD;Zujun Li, MD;Daniel J. Becker, MD;Benjamin P. Levy, MD

June 15th 2014

An 81-year-old Chinese male never-smoker with a medical history of hypertension and hyperlipidemia presented with a productive cough and a 5-lb weight loss over 3 months.